Timo Veromaa, President and CEO of Biotie Therapies, David Cook, CFO and Stephen Bandak, CMO are leaving the company today (30 June).
The Board of Directors of the Finland-based biopharmaceutical firm has appointed Antero Kallio, as the new CEO and Kristian Rantala as CFO, effective 1 July.
Kallio is currently the Site Head of Biotie's operations in Turku, Finland and Kristian Rantala is Vice President Finance.
The responsibilities of the Chief Medical Officer will be divided among the company's research and development team staff members as well as with Acorda Therapeutics' interim Chief Medical Officer Burkard Blank.
Veromaa was appointed President and CEO of Biotie in 2005. He has led the company through a number of pivotal transactions, including financial restructurings, acquisition of Synosia Therapeutics in 2011 and IPO of Biotie in the US in 2015.
'We wish Timo, David and Stephen the best in their future endeavours,' said Ron Cohen, Chairman of the Board of Directors of Biotie.
